Document:

Exhibit

   Exhibit 4.9
AMENDED AND RESTATED CONSULTING AGREEMENT

THIS AMENDED AND RESTATED CONSULTING AGREEMENT (this "Agreement"), dated as of February 17, 2016, is between Aeterna Zentaris Inc., a corporation with an address at 2500-1 PLACE Ville Marie Montréal Québec H3B 1R1, Canada (the "Company"), and Geneviève Lemaire, CPA, CA, CPA (Illinois), with an address at 44 Montée du Bois Franc, Lac-Beauport, Québec, Canada G3B 1Y5 (the “Consultant").
The parties agree as follows:
1.     Consulting Service.  The Consultant agrees that during the term of this Agreement:  
		
	(A)
	The Consultant’s role will be to fill all responsibilities of the position of Vice President, Finance and Chief Accounting Officer of the Company for an interim period, performing the specific duties listed on Exhibit 1 to this Agreement.  The Board of Directors of the Company has appointed you to such office effective as of the termination of the employment of Keith Santorelli at the close of business on February 18, 2016.  As an officer of the Company elected by the Board, you will be covered by the Company’s D&O policy, which will be confirmed by an acknowledgment obtained from our primary D&O carrier.

		
	(B)
	The Consultant will devote best efforts to such position as consultant and an independent contractor to the Company.  In addition, the Consultant will be available to train the new Corporate Controller when this person will be hired and will provide advice and assistance to the Company from time to time as requested by the Company's Audit Committee and Management. The Consultant shall be available during the term of this Agreement to assist the Company as requested by Management and at the Company’s sole discretion to offer consulting, advice, and assistance or to perform other activities related to the finance function of the Company.  The Consultant shall be acting in the capacity of an independent contractor, and not as an employee of the Company.  The Consultant shall not be subject to the direct control or supervision of the Management of the Company with respect to the time spent, research undertaken, or procedures followed in the performance of consulting services rendered hereunder. 

		
	(C)
	The Consultant shall exercise a reasonable degree of skill, prudence and care in performing these services.

		
	(D)
	Nothing contained in this Agreement shall limit or restrict the Consultant from serving as an employee, officer or director of other companies or entities, and the Consultant may provide consulting services for other companies or organizations, provided that such activities do not conflict with the services and activity that the Consultant is rendering to the Company or any of its subsidiaries or the services or activities of the Company and its subsidiaries.

		
	(E)
	The Consultant shall be available to render such consulting services to the Company under this Agreement during the term of this Agreement. The Consultant shall not be obligated to render any services under this Agreement during such period when she is unable to do so due to illness, disability or injury;

		
	(F)
	The Consultant shall not enter into agreements or make commitments on behalf of the Company, except when approved by management and permitted in the delegation of authority approved by the Board of Directors.

		
	(G)
	It is possible that the Consultant will have to travel to fulfill her responsibilities. The Company will reimburse all out of pocket expenses incurred.  

		
	2. 
	Compensation.

		
	(A)
	The Company agrees to pay the Consultant for her services performed under this Agreement at an hourly rate of CDN$170 (one hundred and seventy dollars).  Such fees will be paid directly to the Consultant upon presentation of detailed invoice.  The parties agree that the Consultant shall not be entitled to participate in or to receive benefits pursuant to any Company program customarily made available to Company employees. The Consultant acknowledges that she is not being covered by any worker compensation policy or program provided or managed by the Company. 

		
	(B)
	    At the conclusion of Consultant’s arrangement with the Company on the terms set out herein, Consultant will be paid a bonus in the amount of CDN$20,000.

		
	3. 
	Term and Termination.  The term of this Agreement shall continue indefinitely ("Term"), unless otherwise terminated in accordance with the provisions set forth below.

		
	(A)
	Termination for Cause. The Company may terminate this Agreement at any time for "Just Cause". Termination for Just Cause shall be defined as: (i) If the Consultant shall have engaged in conduct involving fraud, deceit, personal dishonesty, or breach of fiduciary duty; (ii) If the Consultant shall have violated any banking law or regulation, memorandum of understanding, cease and desist order, or other agreement with any banking agency having jurisdiction over the Company which, in the judgment of the Company, has adversely affected, or may adversely affect, the business or reputation of the Company as determined by the Company; (iii) If the Consultant shall have become subject to continuing intemperance in the use of alcohol or drugs which has adversely affected, or may adversely affect, the business or reputation of the Company as determined by the Company; (iv) If the Consultant shall have filed, or had filed against her, any petition under the federal bankruptcy laws or any provincial insolvency laws; or (v) If any regulatory authority having jurisdiction over the Company, or its subsidiaries, initiates any proceedings against the Consultant. 

1

   Exhibit 4.9
AMENDED AND RESTATED CONSULTING AGREEMENT

		
	(B)
	Termination following Recruitment of CFO.  The Company intends to commence a search for a Senior Vice President, Chief Financial Officer in the near future.  The Company cannot predict the duration of the search; however, the Company believes that the search may require five to six months.  The Company will keep you informed of the status of the search and may request that you participate in the review of résumés or that you interview candidates.  In any event, you will be notified when a candidate is hired and this Agreement shall terminate 120 days after the date of hire of the CFO (unless we agree on a different period before this Agreement expires).  

		
	(C)
	Disability or Death.  In the event of the disability or death of the Consultant, this Agreement shall terminate without further action by the Company; provided that the Company shall be obligated to pay the Consultant (or her estate) for any periods of work performed prior to disability or death of the Consultant.

		
	5. 
	Confidential Business.  The Consultant, during the Term of this Agreement, will not, without the express written consent of Company, directly or indirectly communicate or divulge to, or use for her own benefit or for the benefit of any other person, firm, association, or corporation, any trade secrets, proprietary data or other confidential information communicated to or otherwise learned or acquired by the Consultant from the Company while serving as a consultant, except that the Consultant may disclose such matters to the extent that disclosure is (a) requested by the Company or (b) required by a court or other governmental agency of competent jurisdiction.

		
	6. 
	General. 

		
	(A)
	Entire Agreement and Amendments.  This Agreement is the entire agreement between the parties and supersedes all earlier and simultaneous agreements regarding the subject matter. This Agreement may be amended only in a written document, signed by both parties. 

		
	(B)
	    Independent Contractors, Third Party Beneficiaries, and Subcontractors.  The parties acknowledge that they are independent contractors under this Agreement, and except if expressly stated otherwise, neither the Consultant, nor any of her employees or agents, has the power or authority to bind or obligate the Company.  Except if expressly stated, no third party is a beneficiary of this Agreement.  

		
	(C)
	    Assignment.  This Agreement binds and inures to the benefit of the parties' successors and assigns.  This Agreement may not be assigned, delegated, sublicensed or otherwise transferred by the Consultant in whole or in part without the prior written consent of Company.  Any transfer, assignment, delegation or sublicense by the Consultant without such consent is invalid. 

		
	(D)
	    No Waivers, Cumulative Remedies.  A party's failure to insist upon strict performance of any provision of this Agreement is not a waiver of any of its rights under this Agreement.  Except if expressly stated otherwise, all remedies under this Agreement, at law or in equity, are cumulative and nonexclusive. 

		
	(E)
	    Severability.  If any portion of this Agreement is held to be unenforceable, the unenforceable portion must be construed as nearly as possible to reflect the original intent of the parties, the remaining portions remain in full force and effect, and the unenforceable portion remains enforceable in all other contexts and jurisdictions. 

		
	(F)
	    Notices.  All notices, including notices of address changes, under this Agreement must be sent by registered or certified mail or by overnight commercial delivery to the address set forth in this Agreement by each party. 

		
	(G)
	    Captions and Plural Terms.  All captions are for purposes of convenience only and are not to be used in interpretation or enforcement of this Agreement.  Terms defined in the singular have the same meaning in the plural and vice versa. 

		
	(H)
	    Governing Law.  This Agreement shall be governed by the laws of the Province of Québec (without giving effect to internal choice of law rules). 

		
	(I)
	    Language of Agreement.  The parties have expressly requested that the present document be drafted in English. Les parties ont expressément demandé à ce que le présent document soit rédigé en anglais. 

IN WITNESS WHEREOF, the parties execute this Agreement.  Each person who signs this Agreement below represents that such person is fully authorized to sign this Agreement on behalf of the applicable party. 

	
		
	COMPANY
	CONSULTANT

	 
	 

	By: /s/ David A. Dodd
	  By: /s/  Geneviève Lemaire

	Name:  David A. Dodd
	 Name:  Geneviève Lemaire

	Title:  Chairman, President and CEO 
	Title:  CPA, CA, CPA (Illinois)

                                                                                                                                                                         

2

   Exhibit 4.9
AMENDED AND RESTATED CONSULTING AGREEMENT

EXHIBIT 1

As our Chief Accounting Officer, your principal responsibilities will be as follows:
		
	•
	Supervising all other accounting personnel in the US and Germany

		
	•
	Managing the Company’s relationship with PWC

		
	•
	Supervising the monthly and quarterly closes of the Company’s books

		
	•
	Supervising the preparation of quarterly financial statements

		
	•
	Signing the certifications of our filings as required by US and Canadian securities authorities

		
	•
	Developing a plan for transitioning our reporting basis from IFRS to US GAAP and starting the conversion process

		
	•
	Leading the transition into the Company of the new CFO

		
	o
	This process should begin with your proposal of a transition plan for review by me and David Dodd, our CEO

		
	o
	During the transition period, there will be times in which you will need to be present in the Summerville office

		
	•
	Participating in Operating Committee meetings to provide information to other senior managers regarding the Company’s financial condition and the status of your activities

		
	•
	Participating in Board Meetings and Board conference calls, as required of the position of Vice President, Finance and Chief Accounting Officer

3Exhibit 10.37

 

Amended and Restated EMPLOYMENT
AGREEMENT

 

This Amended and Restated EMPLOYMENT AGREEMENT
(the “Agreement”) is made as of the 7th day of May 2015, by and between Albany Molecular Research, Inc., a Delaware
corporation (the “Company”), and Milton Boyer (the “Executive”).

 

WHEREAS, the Executive was an employee of
Oso Biophamaceuticals Manufacturing, LLC (“OsoBio”) and was party to an Employment Agreement dated January 31, 2012
(the “Prior Agreement”); and

 

WHEREAS, on June 1, 2014, OsoBio and the
Company entered into that certain Membership Interest Purchase Agreement by and among Company, the “Buyer” entity named
therein, OsoBio and Oso Biopharm Holdings, LLC, pursuant to which, among other things, at the closing of the transactions contemplated
by such Membership Interest Purchase Agreement, which the parties agreed was effective on July 1, 2014,(the “Closing”),
OsoBio became an indirect wholly owned subsidiary of the Company; and

 

WHEREAS, the parties entered into an Employment
Agreement dated as of June 1, 2014 (the “Original Agreement”) and due to certain changed circumstances, now wish to
modify the Original Agreement as set forth herein, which Amended and Restated Employment Agreement shall supercede and replace
the Original Agreement ; and

 

WHEREAS, the parties hereto desire to assure
that the Executive’s knowledge and familiarity with the business of the Company will continue to be available to the Company
after the Closing.

 

NOW, THEREFORE, in consideration of the
mutual promises and covenants herein contained, the parties agree as follows:

 

1.            Employment.
Subject to the provisions of this Agreement, the Company hereby employs as of the Effective Date the Executive and the Executive
accepts such employment upon the terms and conditions hereinafter set forth. Executive agrees that the Prior Agreement is terminated
and no longer in force and effect as of the Effective Date, which the parties agree was July 1, 2014.

 

2.            Term
of Employment. The term of the Executive’s employment pursuant to this Agreement shall commence on and as of the date
of the Closing (the “Effective Date”) and shall remain in effect for a period of two (2) years from the Effective Date
(the “Term”). Unless either party provides written notice of its intent not to renew the Agreement at least 180 days
prior to the expiration date, the Agreement shall automatically renew for periods of one (1) year (each a “Renewal Term”)
commencing at the second anniversary of the Effective Date and on each subsequent anniversary thereafter. If not renewed, the Agreement
will expire. The period during which the Executive serves as an employee of the Company in accordance with and subject to the provisions
of this Agreement is referred to in this Agreement as the “Term of Employment.” Notwithstanding anything to the contrary
contained herein, this Agreement shall take effect as of the Effective Date, and shall have no legal force or effect whatsoever
prior thereto (or in the event the Closing does not occur for any reason, whether due to termination of the Membership Interest
Purchase Agreement or otherwise).

 

     

     

    

 

3.            Capacity.

 

(a)            Duties.
During the Term of Employment, the Executive shall report directly to Willam S. Marth, CEO or any other person designated by the
President and Chief Executive Officer and (i) shall serve with the title Senior Vice President, Drug Product Manufacturing, (ii)
shall perform such duties and responsibilities as may be reasonably determined by Chairman, President and Chief Executive Officer
or his designate, consistent with the Executive’s title and position, duties and responsibilities as an employee of the Company
as of the Effective Date; provided that such duties and responsibilities shall be within the general area of the Executive’s
experience and skills, and (iii) shall render all services incident to the foregoing.

 

(b)            Extent
of Service. The Executive agrees to diligently serve the interests of the Company and shall devote substantially all of his
working time, attention, skill and energies to the advancement of the interests of the Company and its subsidiaries and affiliates
and the performance of his duties and responsibilities hereunder; provided that nothing in this Agreement shall be construed as
preventing the Executive from (i) investing the Executive’s assets in any entity in a manner not prohibited by Section 7
and in such form or manner as shall not require any material activities on the Executive’s part in connection with the operations
or affairs of the entities in which such investments are made, or (ii) engaging in religious, charitable or other community or
non-profit activities that do not impair the Executive’s ability to fulfill the Executive’s duties and responsibilities
under this Agreement.

 

4.            Compensation.

 

(a)            Salary.
During the Term of Employment, the Company shall pay the Executive a salary (the “Base Salary”) at an annual rate as
shall be determined from time to time by the Chairman, President and Chief Executive Officer or other appropriate person of the
Company consistent with the general policies and practices of the Company; provided, however, that in no event shall such rate
per annum be less than $275,000. Such Base Salary shall be subject to withholding under applicable law and shall be payable in
periodic installments in accordance with the Company’s usual practice for its senior executives, as in effect from time to
time.

 

(b)            Bonus.
Following the Effective Date, goals will be set by the Company for Executive relating to specific objectives for 2014 including
the integration of OsoBio with AMRI and independent OsoBio operating goals. Executive will be eligible to receive a bonus for accomplishment
of such goals of up to 50% (fifty percent) of his Base Salary (the “Initial Bonus”), which bonus would be payable at
the time that bonuses are regularly paid to executives and employees in early 2015. Payment of the Initial Bonus will be made in
the reasonable discretion of Executive’s supervisor and the President and CEO of AMRI; provided, however that the Executive
shall be entitled to receive a bonus for 2014 of not less than $125,000, which shall include any bonus for the partial year that
was paid or is payable to Executive by OsoBio or its shareholders pursuant to any agreement between Executive and any such party
related to or as a condition of the sale of OsoBio by its shareholders. After 2014, which shall be covered by the Initial Bonus
referenced above, the Company shall annually review the performance of the Company and of the Executive during the prior year,
and the Company may provide the Executive with additional compensation as a bonus in accordance with any bonus plan then in effect
from time to time for similarly situated employees of the Company.

 

    	 	2	 

     

    

 

5.            Benefits.

 

(a)            Reimbursement
of Expenses. The Company shall promptly reimburse the Executive for all reasonable business expenses incurred by the Executive
during the Term of Employment in accordance with the Company’s practices for employees of the Company, as in effect from
time to time, including travel to and from Georgia and in accordance with the Company’s regular travel and entertainment
policy.

 

(b)            Vacation.
During the Term of Employment, the Executive shall receive paid vacation annually in accordance with the Company’s practices
for employees of the Company, of which current applicable practice is four (4) weeks.

 

(c)            Company-Leased
Housing and Vehicle. During the Term of Employment, the Company shall provide Executive with a stipend for housing and a Company-leased
vehicle (each of which shall be selected by the Executive). The stipend will be in the amount of $3,500 per month. The current
vehicle lease shall end no later than December 2017 and will not be renewed. The housing stipend shall be evaluated and potentially
discontinued in May 2017. Separation of employment for any reason will result in the immediate termination of both the auto and
home lease payments.

 

(d)            Relocation.
Any time after the Effective Date, the Executive will be eligible for the AMRI Relocation Program for executives. This program
includes reimbursement or direct payment of all costs associated with the closing costs for both sale of the Executive’s
primary residence in Georgia and the purchase, if any, of a new residence at the agreed upon location. The Company will pay for
the physical move of household goods to the new location. The timing and location of such relocation shall be agreed to between
Executive and his supervisor and the President and CEO of AMRI and further details regarding such relocation will be established
at such time. Upon the Executive's relocation, the benefits provided pursuant to Section 5(c) will cease.

 

(e)            Grant
of Company Equity. On the Effective Date, the Company granted to Executive 20,000 shares of restricted stock, such restricted
stock to be granted pursuant to the Company’s 2008 Stock Option and Incentive Plan (the “Plan”). Such restricted
stock will be evidenced by standard agreements to be entered into between Executive and the Company and will vest in equal installments
over 4 (four) years on each anniversary of the date of grant.

 

(f)            Other
Company Benefit Plans. During the Term of Employment, the Executive shall be entitled to participate in any and all medical,
dental, pension and life insurance plans, disability income plans and other employee benefit plans as in effect from time to time
for similarly situated employees of Oso Bio. Such participation shall be subject to (i) the terms of the applicable plan documents,
(ii) generally applicable policies of the Oso Bio and (iii) the discretion of the Board of Directors of the Company or the administrative
or other committee provided for in, or contemplated by, such plan. Compliance with this Section 5(f) shall in no way create or
be deemed to create any obligation, express or implied, on the part of the Company or any subsidiary or affiliate of the Company
with respect to the continuation of any benefit or other plan or arrangement maintained as of or prior to the Effective Date or
the creation and maintenance of any particular benefit or other plan or arrangement at any time after the Effective Date.

 

    	 	3	 

     

    

 

(g)            Tax
Treatment. The Company shall make deductions, withholdings and tax reports with respect to payments and benefits under this
Agreement to the extent that it reasonably and in good faith determines that it is required to make such deductions, withholdings
and tax reports.  Payments under this Agreement shall be in amounts net of any such deductions or withholdings.  Nothing
in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax
effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.

 

6.            Termination
of Employment. Notwithstanding the provisions of Section 2, the Executive’s employment under this Agreement shall terminate
under the following circumstances set forth in this Section 6.

 

For purposes of this Agreement, “Date
of Termination” means (i) if the Executive’s employment is terminated by his death as provided in Section 6(c), the
date of his death; (ii) if the Executive’s employment is terminated due to his permanent disability as provided in Section
6(c), the date on which notice of termination is given and (iii) if the Executive’s employment is terminated under Section
6(e), (A) thirty (30) days after the date on which the Company gives notice of termination or (B) the date on which the Company’s
cure period expires, as applicable.

 

(a)          Mutual
Consent. The Executive’s employment under this Agreement may be terminated at any time by the mutual consent of the Executive
and the Company on such terms as both parties shall mutually agree.

 

(b)          Termination
by the Company for Cause. The Executive’s employment under this Agreement may be terminated by the Company for “Cause”
at any time upon written notice to the Executive without further liability on the part of the Company. For purposes of this Agreement,
a termination shall be for “Cause” if:

 

(i)          the
Executive shall commit an act of fraud, embezzlement, misappropriation or breach of fiduciary duty against the Company or any of
its subsidiaries or affiliates or shall be convicted by a court of competent jurisdiction or shall plead guilty or nolo contendere
to any felony;

 

(ii)         the
Executive shall commit a material breach of any of the covenants, terms or provisions of Section 7 or 8 hereof which breach has
not been cured within fifteen (15) days after delivery to the Executive by the Company of written notice thereof;

 

(iii)        the
Executive shall commit a material breach of any of the covenants, terms or provisions hereof (other than pursuant to Section 7
or 8 hereof) which breach has not been remedied within thirty (30) days after delivery to the Executive by the Company of written
notice thereof; or

 

    	 	4	 

     

    

 

(iv)        the
Executive shall have continuously failed to substantially perform the Executive’s duties hereunder, after written notice
and under circumstances effectively constituting a voluntary resignation of the Executive’s position with the Company.

 

Upon termination for Cause as provided in
this Section 6(b), (x) all obligations of the Company under this Agreement shall thereupon immediately terminate other than any
obligations with respect to (A) earned but unpaid Base Salary, (B) reimbursement for any unreimbursed expenses incurred through
the date of termination, to the extent reimbursable in accordance with Company policy, (C) any accrued but unused vacation time
in accordance with Company policy; and (D) all other payments or benefits (if any) to which the Executive shall be entitled
under the express terms of any applicable benefit plan or arrangement maintained by the Company (the “Accrued Obligations”)
and (y) the Company shall have any and all rights and remedies under this Agreement and applicable law.

 

(c)            Death;
Disability. The Executive’s employment under this Agreement may be terminated by the Company upon the earlier of death
or permanent disability (as defined below) of the Executive continuing for a period of one hundred eighty (180) days. Upon any
such termination of the Executive’s employment, all obligations of the Company under this Agreement shall thereupon immediately
terminate other than any obligations with respect to (i) Accrued Obligations, (ii) bonus payments with respect to the calendar
year within which such termination occurred on the basis of and to the extent contemplated in any bonus plan then in effect with
respect to executives of similar level at the Company, pro-rated on the basis of the number of days of the Executive’s actual
employment hereunder during such calendar year through the Date of Termination, and (iii) in the case of permanent disability,
continuation at the Company’s expense of health insurance benefits (medical and dental) until the first anniversary of the
Date of Termination to the extent permitted under the Company’s group health insurance policy. As used herein, the term “permanent
disability” or “permanently disabled” means the inability of the Executive, by reason of injury, illness or other
similar cause, to perform a major part of his duties and responsibilities in connection with the conduct of the business and affairs
of the Company. The Company shall provide written notice to the Executive of the termination of his employment hereunder due to
permanent disability.

 

(d)            Voluntary
Termination by the Executive. At any time during the Term of Employment, the Executive may terminate his employment under this
Agreement for other than “Good Reason” (as defined in Section 6 (e)) upon thirty (30) days’ prior written notice
to the Company. Upon termination by the Executive as provided in this Section 6(d), all obligations of the Company under this Agreement
shall thereupon immediately terminate other than any obligations with respect to Accrued Obligations.

 

    	 	5	 

     

    

 

(e)            Termination
by the Company Without Cause or by the Executive for Good Reason. The Executive’s employment under this Agreement may
be terminated by the Company at any time without “Cause” (as defined in Section 6(b)) upon thirty (30) days’
prior written notice to the Executive or by the Executive at any time during the Term for “Good Reason”. Any termination
by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under
Section 6(b) and is not a termination on account of death or disability under Section 6(c) shall be deemed a termination without
Cause. Upon any such termination of the Executive’s employment by the Company without Cause or by the Executive for Good
Reason during the Term, all obligations of the Company under this Agreement shall thereupon immediately terminate other than any
obligations with respect to Accrued Obligations. In addition, subject to the Executive signing within the applicable consideration
period a general release of claims in a form and manner satisfactory to the Company and the lapse of any statutory revocation period
(the “Release Requirement”), the Company shall continue to pay the Executive his Base Salary at the rate then in effect
pursuant to Section 4(a) for a period of twelve (12) months from the Date of Termination; provided that the Company shall
make the first payment of such Base Salary continuation at any time determined by the Company within sixty (60) days of the Date
of Termination; provided further that if the sixty (60) day period begins in one calendar year and ends in a second calendar
year, the Base Salary continuation payments shall begin to be paid in the second calendar year by the last day of such sixty (60)
day period. The first such payment of Base Salary continuation shall include payment for all Base Salary that would have been paid
by such date if Base Salary payments had not ceased due to the termination of the Executive’s employment. Also subject to
the Release Requirement, the Company shall (i) pay 100% of the costs to provide up to three (3) months of outplacement support
services at a level appropriate for the Executive’s title and responsibilities and (ii) pay the same share of group medical
and dental plan premiums for the Executive that it pays for active employees at the same site location with the same level of group
medical and dental plan benefits for a period of twelve (12) months from the Date of Termination; provided that such contributions
toward group medical and dental plan continuation coverage shall be pursuant to and subject to the Executive’s election of
COBRA coverage and continued eligibility for such continuation.

 

For purposes of this Agreement, “Good
Reason” shall mean the occurrence of either of the following: (A) a material diminution in the nature or scope of the powers,
duties or responsibilities of the Executive; or (B) a breach by the Company of any of its material obligations hereunder. The Executive
shall provide the Company with reasonable notice and an opportunity to cure the event listed in clause (A) or clause (B) above,
as applicable, within sixty (60) days after the Executive first becomes aware of the occurrence of such event, and the Executive
shall not be entitled to compensation pursuant to this Section 6(e) unless the Company fails to cure such event within a reasonable
period of not less than thirty (30) nor more than forty five (45) days after the Company’s receipt of such notice from the
Executive.

 

7.            Non-Competition
and No Solicitation.

 

(a)            Because
the Executive’s services to the Company are special and because the Executive has access to the Company’s Confidential
Information (as hereinafter defined), during the Term of Employment and for a period of twelve (12) months following the termination,
the Executive shall not, without the express written consent of the Company, directly or indirectly, engage, participate, invest
in, be employed by or assist, whether as owner, part-owner, shareholder, partner, director, officer, trustee, employee, agent or
consultant, or in any other capacity, any Person (as hereinafter defined) other than the Company and its affiliates in the Designated
Industry (as hereinafter defined); provided, however, that nothing herein shall be construed as preventing the Employee from making
passive investments in a Person in the Designated Industry if the securities of such Person are publicly traded and such investment
constitutes less than one percent (1%) of the outstanding shares of capital stock or comparable equity interests of such Person.

 

    	 	6	 

     

    

 

(b)            For
purposes of this Agreement, the following terms have the following meanings:

 

“Person” means an individual,
a corporation, an association, a partnership, a limited liability company, an estate, a trust and any other entity or organization;
and

 

“Designated Industry” means
chemistry and biology services, the drug development and drug product manufacturing industries and any other business conducted
by OSOBio or the Company during the Executive’s employment with OSOBio and the Company. Because the Company’s business
is worldwide in scope, the Designated Industry includes such business activities in any location in the world.

 

(c)            For
a period of twelve (12) months following the termination of the Executive’s employment under this Agreement for any reason,
the Executive shall not, directly or indirectly, alone or as a member of any partnership or limited liability company or entity,
or as an officer, director, shareholder, or employee of any corporation or entity, solicit, divert or take away, or attempt to
divert or take away, the business or patronage of any current or former client, customer or account of the Company; provided, that
this sub-section shall be limited to clients, customers or accounts of the Company who were clients, customers or accounts of the
Company at any time during the Executive's employment with the Company.

 

(d)            For
a period of twelve (12) months following the termination of the Executive’s employment under this Agreement for any reason,
the Executive shall not, directly or indirectly, alone or as a member of any partnership or limited liability company or entity,
or as an officer, director, shareholder, or employee of any corporation or entity (a) solicit or otherwise encourage any employee
or independent contractor of the Company to terminate his/her relationship with the Company, or (b) recruit, hire or solicit for
employment or for engagement as an independent contractor, any person who is or was employed by the Company at any time during
the Executive’s employment with the Company. This sub-section shall not apply to persons whose employment and/or retention
with the Company has been terminated for a period of twenty-four (24) months or longer.

 

(e)            If
any restriction set forth in this Section 7 is found by any court of competent jurisdiction to be unenforceable because it extends
for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be rewritten
by the court to extend only over the maximum period of time, range of activities or geographic area as to which may be enforceable.

 

    	 	7	 

     

    

 

8.            Confidentiality.
In the course of performing services hereunder and otherwise, the Executive has had, and it is anticipated that the Executive will
from time to time have, access to confidential records, data, customer lists, trade secrets, technology and similar confidential
information owned or used in the course of business by the Company and its subsidiaries and affiliates (the “Confidential
Information”). The Executive agrees (i) to hold the Confidential Information in strict confidence, (ii) not to disclose the
Confidential Information to any Person (other than in the regular business of the Company), and (iii) not to use, directly or indirectly,
any of the Confidential Information for any competitive or commercial purpose; provided, however, that the limitations set forth
above shall not apply to any Confidential Information which (A) is then generally known to the public, (B) became or becomes generally
known to the public through no fault of the Executive, or (C) is disclosed in accordance with an order of a court of competent
jurisdiction or applicable law. Upon termination of the Executive’s employment with the Company, all data, memoranda, customer
lists, notes, programs and other papers and items, and reproductions thereof relating to the foregoing matters in the Executive’s
possession or control, shall be returned to the Company and remain in its possession. This Section 8 shall survive the termination
of this Agreement for any reason.

 

9.            Conflicting
Agreements. The Executive hereby represents and warrants that the execution of this Agreement and the performance of his obligations
hereunder will not (after giving effect to the termination of the Prior Agreement hereby on the Effective Date) breach or be in
conflict with any other agreement to which he is a party or is bound, and that he is not now subject to any covenants which would
affect the performance of his obligations hereunder. As of the Effective Date, the Executive is not performing any other duties
for, and is not a party to any similar agreement with, any Person competing with the Company or any of its affiliates.

 

10.         Severability.
In case any of the provisions contained in this Agreement shall for any reason be held to be invalid, illegal or unenforceable
in any respect, any such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement, but
this Agreement shall be construed as if such invalid, illegal or unenforceable provision had been limited or modified (consistent
with its general intent) to the extent necessary to make it valid, legal and enforceable, or if it shall not be possible to so
limit or modify such invalid, illegal or unenforceable provision or part of a provision, this Agreement shall be construed as if
such invalid, illegal or unenforceable provision or part of a provision had never been contained in this Agreement.

 

11.         Litigation
and Regulatory Cooperation. During and after the Executive’s employment, the Executive shall cooperate fully with the
Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or
on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company.
The Executive’s full cooperation in connection with such claims or actions shall include, but not be limited to, being available
to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient
times. During and after the Executive’s employment, the Executive also shall cooperate fully with the Company in connection
with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates
to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive
for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant
to this Section 11. This Section 11 shall survive the termination of the Executive’s employment under this Agreement for
any reason.

 

    	 	8	 

     

    

 

12.         Arbitration
of Disputes. Except as provided in Section 13, any dispute or controversy arising under or in connection with this Agreement
or otherwise arising out of the Executive’s employment or the termination of that employment (including, without limitation,
any claims of unlawful employment discrimination or other statutory claims) shall be settled exclusively by arbitration in Albany,
New York, in accordance with the rules of the American Arbitration Association then in effect. Judgment may be entered in any court
having jurisdiction. In the event that the Company terminates the Executive’s employment for Cause under Section 6(b) and
the Executive contends that Cause did not exist, then the Company’s only obligation with respect to the dispute concerning
whether Cause exists under Section 6(b) shall be to submit such claim to arbitration and the only issue before the arbitrator will
be whether the Executive was in fact terminated for Cause. If the arbitrator determines that the Executive was not terminated for
Cause by the Company, then the only remedies that the arbitrator may award are (i) payment of amounts which would have been payable
if the Executive’s employment had been terminated under Section 6(e), (ii) the costs of arbitration, (iii) the Executive’s
reasonable attorneys’ fees, and (iv) all rights and benefits granted or in effect with respect to the Executive under the
Company’s stock option plans and agreements with the Executive pursuant thereto that have not been provided due to the Company’s
determination concerning the circumstances leading to the termination of the Executive’s employment, with the vesting and
exercise of any stock options and the forfeitability of any stock-based grants held by the Executive to be governed by the terms
of such plans and the related agreements between the Executive and the Company. If the arbitrator finds that the Executive’s
employment was terminated for Cause, the arbitrator will be without authority to award the Executive anything, and the parties
will each be responsible for their own attorneys’ fees, and they will divide the costs of arbitration equally. Furthermore,
should a dispute occur concerning the Executive’s mental or physical capacity as described in Section 6(c), a doctor selected
by the Executive and a doctor selected by the Company shall be entitled to examine the Executive. If the opinion of the Company’s
doctor and the Executive’s doctor conflict, the Company’s doctor and the Executive’s doctor shall together agree
upon a third doctor, whose opinion shall be binding. This Section 12 shall survive the termination of the Executive’s employment
under this Agreement for any reason.

 

13.         Specific
Performance. Notwithstanding Section 12 hereof, it is specifically understood and agreed that any breach of Section 7 or 8
of this Agreement by the Executive is likely to result in irreparable injury to the Company and its subsidiaries and affiliates,
that the remedy at law alone will be inadequate remedy for such breach and that, in addition to any other remedy it may have, the
Company shall be entitled to enforce the specific performance of this Agreement by the Executive and to seek both temporary and
permanent injunctive relief (to the extent permitted by law), without the necessity of proving actual damages. Therefore, any claim
based on an alleged breach of Section 7 or 8 of this Agreement shall not be subject to Section 12 hereof unless otherwise agreed.
To the extent that any court action is permitted consistent with or to enforce Section 7 or 8 of this Agreement or to enforce Section
12, the parties hereby agree to the sole and exclusive jurisdiction of the Supreme Court of the State of New York (Albany County)
and the United States District Court for the Northern District of New York (City of Albany). Accordingly, with respect to any such
court action, the Executive (i) submits to the personal jurisdiction of such courts, (ii) consents to service of process, and (iii)
waives any other requirement (whether imposed by statute, rule of court or otherwise) with respect to personal jurisdiction or
service of process.

 

    	 	9	 

     

    

 

14.         Notices.
All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given
(i) when delivered by hand, (ii) when transmitted by facsimile and receipt is acknowledged, or (iii) if mailed by certified or
registered mail with postage prepaid, on the third business day after the date on which it is so mailed:

 

To the Company:

 

Albany Molecular Research, Inc.

21 Corporate Circle

Albany, New York 12203-5154

Facsimile: (518) 867-4375

Attention: Senior Vice President of Human Resources 

 

To the Executive, to the address on file with the Company.

 

or to such other address of which any party may notify the other
parties as provided above. Notices shall be effective as of the date of such delivery or mailing.

 

15.         Amendment;
Waiver. This Agreement shall not be amended, modified or discharged in whole or in part except by an Agreement in writing signed
by both of the parties hereto. The failure of either of the parties to require the performance of a term or obligation or to exercise
any right under this Agreement or the waiver of any breach hereunder shall not prevent subsequent enforcement of such term or obligation
or exercise of such right or the enforcement at any time of any other right hereunder or be deemed a waiver of any subsequent breach
of the provision so breached, or of any other breach hereunder.

 

16.         Successors
and Assigns. This Agreement shall inure to the benefit of successors of the Company by way of merger, consolidation or transfer
of all or substantially all of the assets of the Company, and may not be assigned by the Executive. The Company shall require any
successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business
or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required
to perform it if no succession had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to
the effectiveness of any succession shall be a material breach of this Agreement.

 

17.         Entire
Agreement. This Agreement constitutes the entire agreement between the parties concerning the subjects hereof and supersedes
all prior understandings and agreements between the parties relating to the subject matter hereof, including without limitation
the Prior Agreement.

 

18.         Governing
Law. This Agreement shall be construed and regulated in all respects under the laws of the State of New York.

 

19.         Counterparts.
This Agreement may be executed in counterparts, each of which when so executed and delivered shall be taken to be an original,
but such counterparts shall together constitute one and the same document.

 

    	 	10	 

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Amended and Restated Agreement as of the day and year first above written.

 

	 	ALBANY MOLECULAR RESEARCH, INC.
	 	 
	 	By: /s/ William S. Marth
	 	 
	 	EXECUTIVE:
	 	 
	 	/s/ Milton Boyer
	 	Milton Boyer

 

    	 	11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]